Rationale for Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Hormone-Naïve Prostate Cancer

Despite advances in treatment for metastatic prostate cancer, patients eventually progress to castrate-resistant disease and ultimately succumb to their cancer. Androgen deprivation therapy (ADT) is the standard treatment for metastatic prostate cancer and has been shown to improve median time to progression and median survival time. Research suggests that castrate-resistant clones may be present early in the disease process prior to the initiation of ADT. These clones are not susceptible to ADT and may even flourish when androgen-responsive clones are depleted. Stereotactic body radiation therapy (SBRT) is a safe and efficacious method of treating clinically localized prostate cancer and metastases. In patients with a limited number of metastatic sites, SBRT may have a role in eliminating castrate-resistant clones and possibly delaying progression to castrate-resistant disease

Baseline patient characteristics.

<p>Baseline patient characteristics.</p

Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System^® for the treatment of hepatocellular carcinoma

<div><p>Purpose</p><p>To review the initial imaging responses after drug-eluting embolic trans-arterial chemoembolization (DEE-TACE) delivered with the Surefire Infusion System ^® for the treatment of hepatocellular carcinoma (HCC).</p><p>Methods</p><p>Single center retrospective evaluation of patients who underwent DEE-TACE for HCC, delivered with SIS. Information was gathered from available medical records. Treatment response rates were assessed using the modified Response Evaluation Criteria in Solid Tumors criteria. Assessment of adverse events was categorized per Common Terminology Criteria for Adverse Events version 4.03.</p><p>Results</p><p>Twenty-two patients with 39 hepatocellular carcinoma lesions were treated with the surefire infusion system. Complete response was demonstrated in 32% of patients and 54% of lesions after a single treatment session. Overall disease response was demonstrated in 91% of patients and 85% of lesions after a single treatment. No grade 3 or higher elevations in liver function tests were demonstrated in the short-term.</p><p>Conclusion</p><p>SIS delivered DEE-TACE leads to a higher than expected initial response in patients with HCC.</p></div

Disease response per lesion based on mRECIST criteria.

<p>Disease response per lesion based on mRECIST criteria.</p

Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System^® for the treatment of hepatocellular carcinoma - Fig 2

<p><b>(A)</b> Initial MRI demonstrating a 3.5 cm hyperenhancing right lobe mass, LIRADS-5 for HCC. <b>(B)</b> Post embolization MRI demonstrating complete response to treatment.</p